“…Liraglutide, an agonist of the glucagon-like peptide-1 receptor (GLP-1R), was launched in China in October 2011. As a new GLP-1R agonist, liraglutide can control blood sugar level effectively, reduce body weight and improve systolic blood pressure, which suggest that liraglutide has a broad clinical application prospect (6). However, in the preclinical stage of drug development, medullary thyroid cancer had been observed from laboratory rodent studies following treatment with GLP-1R activators.…”